CTSA Trial Innovation Network Early Vision & Goals MONICA SHAH, MD DIRECTOR, TRIAL INNOVATION NETWORK

Size: px
Start display at page:

Download "CTSA Trial Innovation Network Early Vision & Goals MONICA SHAH, MD DIRECTOR, TRIAL INNOVATION NETWORK"

Transcription

1 CTSA Trial Innovation Network Early Vision & Goals MONICA SHAH, MD DIRECTOR, TRIAL INNOVATION NETWORK

2 What Do They Have in Common? Hammer M. Harvard Business Review, 2004.

3 What Do They Have in Common? Operational Innovation Inventing and deploying new ways of doing work Hammer M. Harvard Business Review, 2004.

4 Clinical Trials Opportunity for Operational Innovation Califf RM et al. JAMA 2012; Hirsch BR et al. JAMA Intern Med 2013; Goswami ND et al. PLOS One 2013; Alexander KP et al. JAHA 2013;Todd JL et al. Annals ATS 2013; Inrig JK et al. Am J Kidney Dis 2014

5 Clinical Trials Opportunity for Operational Innovation Results of Current Work Models Small, single-center studies Variations in rigor Poor enrollment Decreased scientific impact Operational Challenges Parallel research universe Fragmented infrastructure Huge budgets, misaligned incentives Lack of collaborative efforts Califf RM et al. JAMA 2012; Hirsch BR et al. JAMA Intern Med 2013; Goswami ND et al. PLOS One 2013; Alexander KP et al. JAHA 2013;Todd JL et al. Annals ATS 2013; Inrig JK et al. Am J Kidney Dis 2014

6 Clinical Trials Opportunity for Operational Innovation Results of Current Work Models Opportunity for Operational Innovation Small, single-center studies Variations in rigor Poor enrollment Decreased scientific impact Invent & deploy new Operational Challenges approaches Parallel research universe to clinical trials Fragmented infrastructure Huge budgets, misaligned incentives Lack of collaborative efforts Califf RM et al. JAMA 2012; Hirsch BR et al. JAMA Intern Med 2013; Goswami ND et al. PLOS One 2013; Alexander KP et al. JAHA 2013;Todd JL et al. Annals ATS 2013; Inrig JK et al. Am J Kidney Dis 2014

7 NIH Clinical Trials Opportunity for Operational Excellence NIH Budget FY 2015 $3.2 B ~10% Clinical Trials $27.1 B NIH Budget Office; Mullard A. Nature Reviews Drug Disc 2016; GAO Report, 2016; Innovation for Healthier Americans, 2015

8 NIH Clinical Trials Opportunity for Operational Excellence NIH Budget FY 2015 Results of Current Work Models $3.2 B ~10% Clinical Trials Large unobligated balances Trials not finishing on time or within budget Decreased return on research investments Decreased public trust $27.1 B Operational Challenge Enhance stewardship & accountability of NIH clinical trials NIH Budget Office; Mullard A. Nature Reviews Drug Disc 2016; GAO Report, 2016; Innovation for Healthier Americans, 2015

9 NIH Clinical Trials Opportunity for Operational Excellence NIH Budget FY 2015 Results of Current Work Models $3.2 B ~10% $27.1 B Opportunity for Clinical Trials Large unobligated balances Trials Operational not finishing on Excellence time or within budget Decreased return on research investments Execute trials Decreased public better, trust faster, & more Operational Challenge cost-effectively Enhance stewardship & accountability of NIH clinical trials NIH Budget Office; Mullard A. Nature Reviews Drug Disc 2016; GAO Report, 2016; Innovation for Healthier Americans, 2015

10 Imagine A Clinical Trials Superhighway A Network that Accelerates the Translation of Novel Interventions to Evidence Based Treatments Single IRB Reliance Model Master Contracts Harmonized Data Collection Streamlined Protocols Poised Research Teams Patient Engagement

11 Trial Innovation Network Mission Leverage, in an unprecedented way, the talent, expertise, & resources of the CTSA Program to transform clinical trials Collaborative national Network Accelerate planning & implementation of high quality multi-center trials & studies Provide more treatments to more patients Improve public health Create a national laboratory to study, understand, and improve multi-center clinical trials

12 Trial Innovation Network What Is It? CTSA Hubs Partners NIH ICs Federal Non-federal Network Center Collaborative Strategic Management Partners Patients Trial Innovation Centers (TICs) NCATS & Network Exec. Comm. & CTSA Recruitment Innovation Centers (RICs)

13 Partnership Scientific Questions Supported By: NIH Institutes Industry Other Partners Trial Innovation Network How Will It Work? Operational Excellence Doing Trials Better, Faster, & More Cost- Efficiently Trial Innovation Network Results New Science Studies that Finish on Time & within Budget Generate Evidence to Change Clinical Practice Early Protocols CTSA Hubs RICS NCATS TICS Robust Clinical Trials Operational Questions Supported By: NCATS Operational Innovation Testing New Approaches to Clinical Trials Recruitment, Contracts, IRB, Other Results New Operational Approaches Generate Evidence to Change Research Practice

14 Trial Innovation Network Key Elements Infrastructure Elements o Single IRB Reliance Model SMART IRB Model o Strong Business Models Master contracts Streamlined budgeting Clear workflows o Streamlined Protocols Master protocol & CRF templates Common data elements Protocol review committee o Poised Research Teams Standardized site training o Harmonization Informatics Collaboration Elements o Clear Organization Structure supports collaboration & early engagement o Clear Communication Regular meetings to share and discuss plans with key partners Trial Innovation Network Website o Foster Relationships Teams that focus on collaboration with CTSA Hubs, NIH Institutes, Patients, Other Partners o Evidence Based Learning & Improvement Performance Metrics o Dissemination Plan Focus on engagement & impact Publications & data sharing

15 Trial Innovation Network Leveraging Operational Innovations from the CTSA Program Master Contracts SMART IRB Reliance Platform Standards for Competencies & Training in Clinical Trials EHR Based Recruitment

16 Trial Innovation Network What Is the Added Value? For Investigators One-stop shopping to implement clinical trials TICS & RICS expertise in operational innovation & operational excellence CTSA Hubs broad expertise; large, diverse patient populations More competitive clinical trials applications for NIH ICs For NIH Institutes and Industry Partners Trials completed on time and within budget Shared NIH mission to innovate & transform clinical trials & optimize stewardship

17 Trial Innovation Network Timeline Collaborative Strategic Planning & Management First 6 Months May NCATS Council June Awards Released Develop Network Strategic Plan Launch Demonstration studies Year 1 Demonstrate & disseminate key elements of superhighway Year 2 Launch large scale clinical trials Operationalize SMART IRB Model, Master Contracts, Workflows, Other Strategic Priorities in Demonstration Studies

18 Trial Innovation Network Demonstration Studies To be implemented immediately Small clinical trials & studies (n ~200) testing simple, low-risk interventions Ideal candidates R01 clinical trial applications Reviewed but pending funding decisions Early stage investigators Feasibility analysis of entry criteria

19 Trial Innovation Network NCATS Team Name Monica Shah Michelle Culp Todd Wilson Mary Purucker Ken Gersing Kat Schwartz Patricia Jones Tiina Urv Stacia Fleisher Redonna Chandler Petra Kaufmann Role Director, Trial Innovation Network Director, Clinical Operations Program Officer Director, CTSA Hub Program Director, Biomedical Informatics Program Analyst, Trial Innovation Network Program Officer Program Officer Deputy Director, Office of Grants Management Deputy Director, DCI Director, DCI

20 Trial Innovation Network The Future Collaboration key to transform the clinical trials enterprise & optimize stewardship Trial Innovation Network Operational Excellence & Operational Innovation Resource for scientific community & NIH NCATS welcomes your input, engagement, & partnership as we develop the Trial Innovation Network Program Contacts

21 Trial Innovation Network A Historic Opportunity to Accelerate Translation Through Operational Innovation, Operational Excellence & Collaboration

Leading Efforts to Tackle Roadblocks & Leverage Efficiencies. Jamie Roberts, MPH, MA, CCRP Director, Research Networks Duke CTSI

Leading Efforts to Tackle Roadblocks & Leverage Efficiencies. Jamie Roberts, MPH, MA, CCRP Director, Research Networks Duke CTSI Leading Efforts to Tackle Roadblocks & Leverage Efficiencies Jamie Roberts, MPH, MA, CCRP Director, Research Networks Duke CTSI It takes a really long time Accelerate Translation The Vision for a Big,

More information

Christopher P. Austin, M.D. Director, NCATS IOM CTSA Review Committee January 24, 2013

Christopher P. Austin, M.D. Director, NCATS IOM CTSA Review Committee January 24, 2013 Christopher P. Austin, M.D. Director, NCATS IOM CTSA Review Committee January 24, 2013 Basic Laboratory Research Clinical Research Improved Public Health Translational Research Population Research Basic

More information

Evaluation of the Prime Partnership between Accelence and Quintiles. James Brook Senior Director, Head Site Management Western Europe, Quintiles

Evaluation of the Prime Partnership between Accelence and Quintiles. James Brook Senior Director, Head Site Management Western Europe, Quintiles Evaluation of the Prime Partnership between Accelence and Quintiles James Brook Senior Director, Head Site Management Western Europe, Quintiles Copyright 2013 Quintiles Revised July 2013 7 BILLION HUMANS

More information

University of Utah Annual IRB Member Training Ann Johnson, PhD Associate Director Institutional Review Board

University of Utah Annual IRB Member Training Ann Johnson, PhD Associate Director Institutional Review Board University of Utah Annual IRB Member Training 2016 Ann Johnson, PhD Associate Director Institutional Review Board Overview of NIH policy on the use of a Single IRB for multi site research (and other federal

More information

Webinar Tips Please mute your phone. Please do not put the call on hold. There will be time for questions after the presentation.

Webinar Tips Please mute your phone. Please do not put the call on hold. There will be time for questions after the presentation. Webinar Tips Please mute your phone. Please do not put the call on hold. There will be time for questions after the presentation. Carolinas Collaborative Pilot RFA Webinar May 8, 2017 Partners Overview

More information

CIRB in your future?

CIRB in your future? CIRB in your future? Flexibility Tips! Rebecca Abel* Ann Johnson^ Julie Ozier* Emily Serdoz* Megan Kasimatis Singleton + *Vanderbilt University ^University of Utah + Johns Hopkins University Agenda Overview:

More information

Progress Through Partnership: Actively Engaging Patient Groups in the Clinical Research Process

Progress Through Partnership: Actively Engaging Patient Groups in the Clinical Research Process Progress Through Partnership: Actively Engaging Patient Groups in the Clinical Research Process Petra Kaufmann, MD, MSc, FAAN Director, Division of Clinical Innovation NCATS/NIH DIA MEETING, WASHINGTON

More information

Recruiting and Retention (R&R) for Human Subjects Research: Part 1 Inventory and Open Discussion

Recruiting and Retention (R&R) for Human Subjects Research: Part 1 Inventory and Open Discussion Recruiting and Retention (R&R) for Human Subjects Research: Part 1 Inventory and Open Discussion Ariana Winder, CCRP Penn State CTSI Bench to Bedside and Beyond (B3) Seminar Series October 19, 2017 Objectives

More information

Webinar Tips Please mute your phone. Please do not put the call on hold. There will be time for questions after the presentation.

Webinar Tips Please mute your phone. Please do not put the call on hold. There will be time for questions after the presentation. Webinar Tips Please mute your phone. Please do not put the call on hold. There will be time for questions after the presentation. Carolinas Collaborative Pilot RFA Webinar June 29, 2018 Partners Overview

More information

1201 Maryland Avenue SW, Suite 900, Washington, DC ,

1201 Maryland Avenue SW, Suite 900, Washington, DC , 1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org May 31, 2012 Dockets Management Branch (HFA-305) Food and Drug Administration 5600 Fishers Lane, Rm. 1061 Rockville, MD

More information

The Strategic Planning Process and Optimal Strategic Alternatives COOK COUNTY HEALTH AND HOSPITALS SYSTEM BOARD MEETING MONDAY, MAY 23, 2016

The Strategic Planning Process and Optimal Strategic Alternatives COOK COUNTY HEALTH AND HOSPITALS SYSTEM BOARD MEETING MONDAY, MAY 23, 2016 The Strategic Planning Process and Optimal Strategic Alternatives COOK COUNTY HEALTH AND HOSPITALS SYSTEM BOARD MEETING MONDAY, MAY 23, 2016 1 Strategic Planning Process - Mission To deliver integrated

More information

TransCelerate Overview. Tozheg Roshankar

TransCelerate Overview. Tozheg Roshankar TransCelerate Overview Tozheg Roshankar 11, Aug, 2016 TransCelerate is a not for profit entity created to drive collaboration Our vision To improve the health of people around the world by accelerating

More information

THE IMPACT OF THE AFFORDABLE CARE ACT (ACA) ON CANCER RESEARCH, CARE, AND PREVENTION

THE IMPACT OF THE AFFORDABLE CARE ACT (ACA) ON CANCER RESEARCH, CARE, AND PREVENTION THE IMPACT OF THE AFFORDABLE CARE ACT (ACA) ON CANCER RESEARCH, CARE, AND PREVENTION William S. Dalton, PhD, MD AACR April 17, 2016 Designing a Federated Model To Support Research & Healthcare Offices

More information

DEVELOPING CLINICAL TRIALS INFRASTRUCTURE

DEVELOPING CLINICAL TRIALS INFRASTRUCTURE DEVELOPING CLINICAL TRIALS INFRASTRUCTURE SESSION IV of IOM Workshop: Envisioning a Transformed Clinical Trials Enterprise in the United States: Establishing an Agenda for 2020 PAUL EISENBERG PETRA KAUFMANN

More information

Summary of Provisions in 21 st Century Cures Act (H.R. 6) as passed by full House of Representatives, July 10, 2015

Summary of Provisions in 21 st Century Cures Act (H.R. 6) as passed by full House of Representatives, July 10, 2015 Pediatric-Specific Provisions Summary of Provisions in 21 st Century Cures Act (H.R. 6) as passed by full House of Representatives, July 10, 2015 Requires the NIH to complete a strategic plan, and in the

More information

GW Human Resources Strategic Plan

GW Human Resources Strategic Plan GW Human Resources Strategic Plan 2017-2021 OUR VISION We aspire to develop a diverse and engaged workforce to lead GW to excellence. OUR MISSION The mission of Human Resources is: to serve as an effective

More information

New Health Data Economy: Strategic Partnerships with Life Sciences Company

New Health Data Economy: Strategic Partnerships with Life Sciences Company New Health Data Economy: Strategic Partnerships with Life Sciences Company Pravin R Jadhav Sr. Director, Innovative Data Solutions Otsuka Data Sciences Otsuka Pharmaceutical Development and Commercialization

More information

North Carolina Translational and Clinical Sciences (NC TraCS) Institute Integrated home of the Clinical and Translational Science Awards (CTSA)

North Carolina Translational and Clinical Sciences (NC TraCS) Institute Integrated home of the Clinical and Translational Science Awards (CTSA) North Carolina Translational and Clinical Sciences (NC TraCS) Institute Integrated home of the Clinical and Translational Science Awards (CTSA) What is Translational Research? Translational research includes

More information

Lili M. Portilla, MPA Acting Director, Office of Policy, Communications and Strategic Alliances National Center for Advancing Translational Sciences

Lili M. Portilla, MPA Acting Director, Office of Policy, Communications and Strategic Alliances National Center for Advancing Translational Sciences Lili M. Portilla, MPA Acting Director, Office of Policy, Communications and Strategic Alliances National Center for Advancing Translational Sciences (NCATS), NIH GUIRR Meeting, October 9, 2012 Established

More information

William Barsan, MD SIREN Clinical Coordinating Center

William Barsan, MD SIREN Clinical Coordinating Center William Barsan, MD SIREN Clinical Coordinating Center Evolution not creation Specific aims 1.diligently recruit, efficiently perform, and widely disseminate the most scientifically and clinically important

More information

June 7, Harold E. Varmus, MD Director National Cancer Institute 31 Center Drive Building 31 Room 11A48 MSC 2590 Bethesda, Maryland

June 7, Harold E. Varmus, MD Director National Cancer Institute 31 Center Drive Building 31 Room 11A48 MSC 2590 Bethesda, Maryland Harold E. Varmus, MD Director National Cancer Institute 31 Center Drive Building 31 Room 11A48 MSC 2590 Bethesda, Maryland 20892-2590 Dear Harold: Thank you, again, for taking the time to come to ASCO

More information

The Yale Open Data Access (YODA) Project: Lessons Learned in Data Sharing

The Yale Open Data Access (YODA) Project: Lessons Learned in Data Sharing The Yale Open Data Access (YODA) Project: Lessons Learned in Data Sharing Grand Rounds: A Shared Forum of the NIH HCS Collaboratory and PCORnet June 30, 2017 Joseph S. Ross, MD, MHS Section of General

More information

PAREXEL STRATEGIC PARTNERSHIPS. Optimizing relationships for shorter time to market

PAREXEL STRATEGIC PARTNERSHIPS. Optimizing relationships for shorter time to market PAREXEL STRATEGIC PARTNERSHIPS Optimizing relationships for shorter time to market YOUR JOURNEY. OUR MISSION. Delivering a more collaborative and operationally efficient relationship so you can reach your

More information

THREE -YEAR STRATEGIC PLAN

THREE -YEAR STRATEGIC PLAN THREE -YEAR STRATEGIC PLAN 2017 18 2019 20 About ICES Population-based health research that makes a difference Since its inception in 1992, the Institute for Clinical Evaluative Sciences (ICES) has led

More information

A Potential Innovative CMC Solution: Responding To Public Health Needs With An Accelerated Clinical Pathway A Vaccine Example

A Potential Innovative CMC Solution: Responding To Public Health Needs With An Accelerated Clinical Pathway A Vaccine Example A Potential Innovative CMC Solution: Responding To Public Health Needs With An Accelerated Clinical Pathway A Vaccine Example January 2018 Natalie A. Christian Integrated Development and Supply Team Lead

More information

CHSOR. Johns Hopkins Clinical Data Opportunities for Clinical and Translational Research. Baltimore, 6 Feb 2018

CHSOR. Johns Hopkins Clinical Data Opportunities for Clinical and Translational Research. Baltimore, 6 Feb 2018 Johns Hopkins Clinical Data Opportunities for Clinical and Translational Research Christopher G. Chute, MD DrPH Bloomberg Distinguished Professor of Health Informatics Professor of Medicine, Public Health,

More information

TRANSFORMING CLINICAL RESEARCH FOR FASTER ACCESS TO INNOVATIVE MEDICINES. Establishing the Value of EHR4CR for Pharmaceutical Industry

TRANSFORMING CLINICAL RESEARCH FOR FASTER ACCESS TO INNOVATIVE MEDICINES. Establishing the Value of EHR4CR for Pharmaceutical Industry TRANSFORMING CLINICAL RESEARCH FOR FASTER ACCESS TO INNOVATIVE MEDICINES Establishing the Value of EHR4CR for Pharmaceutical Industry BACKGROUND In the current healthcare environment, bringing a new drug

More information

MANAGING AND INTEGRATING CLINICAL TRIAL DATA: A Challenge for Pharma and their CRO Partners

MANAGING AND INTEGRATING CLINICAL TRIAL DATA: A Challenge for Pharma and their CRO Partners MANAGING AND INTEGRATING CLINICAL TRIAL DATA: A Challenge for Pharma and their CRO Partners Within the Pharmaceutical Industry, nothing is more fundamental to business success than bringing drugs and medical

More information

Genetic Research at Intermountain Healthcare. Marc S. Williams, MD, FAAP, FACMG Director, Clinical Genetics Institute Feb.

Genetic Research at Intermountain Healthcare. Marc S. Williams, MD, FAAP, FACMG Director, Clinical Genetics Institute Feb. Genetic Research at Intermountain Healthcare Marc S. Williams, MD, FAAP, FACMG Director, Clinical Genetics Institute Feb. 12, 2009 Objectives Describe research philosophy at Intermountain Goals of genetics

More information

Summary of Day 1. Christopher Granger

Summary of Day 1. Christopher Granger Summary of Day 1 Christopher Granger 508 million tweets Across the globe 2008 to 2010 Science Sept 30 2011 Selected Points Large simple trials are not so simple, and can also be called large streamlined

More information

Large, Simple Trials Policy Needs: Ethics, Trial Processes

Large, Simple Trials Policy Needs: Ethics, Trial Processes Large, Simple Trials Policy Needs: Ethics, Trial Processes Conflicts I have and continue to conduct simple and complex trials funded by industry, NIH and foundations Industry relations can be found at

More information

March 5, Discussion Guide

March 5, Discussion Guide March 5, 2014 Discussion Guide Biomedical Innovation: Identifying Challenges and Prioritizing Needs in Medical Device Research and Development Introduction Medical device innovation in the United States

More information

Governing Interinstitutional

Governing Interinstitutional Governing Interinstitutional Research John F. Steiner, MD, MPH Senior Director Institute for Health Research Kaiser Permanente Colorado Chairman, Kaiser Permanente National Research Council Governing Board

More information

Real World Evidence Generation in the 21 st Century: National Evaluation System for health Technology (NEST)

Real World Evidence Generation in the 21 st Century: National Evaluation System for health Technology (NEST) Real World Evidence Generation in the 21 st Century: National Evaluation System for health Technology (NEST) Bill Murray, President & CEO IDEAL Conference Presentation May 5, 2017 1 www.mdic.org Vision

More information

On behalf of the Cystic Fibrosis Foundation (CFF) and the 30,000 people with cystic

On behalf of the Cystic Fibrosis Foundation (CFF) and the 30,000 people with cystic Robert J. Beall, Ph.D. President and Chief Executive Officer Cystic Fibrosis Foundation On behalf of the Cystic Fibrosis Foundation (CFF) and the 30,000 people with cystic fibrosis (CF) in the United States,

More information

Clinical and Translational Research: Expectations and Goals

Clinical and Translational Research: Expectations and Goals Clinical and Translational Research: Expectations and Goals Daniel E. Ford, M.D., M.P.H. Director, Institute for Clinical and Translational Research Vice Dean for Clinical Investigation Clinical Research

More information

STRATEGY FORWARD. University of Iowa Health Care Integrated Strategic Plan Approved Strategies for FY18

STRATEGY FORWARD. University of Iowa Health Care Integrated Strategic Plan Approved Strategies for FY18 STRATEGY FORWARD University of Iowa Health Care Integrated Strategic Plan 2017-2020 Approved Strategies for FY18 1 What will success look like? University of Iowa Health Care Strategic Plan 2017-2020:

More information

Development of a Dual University System Health Research Partnership as a Foundation for the Sustainable Development Goals

Development of a Dual University System Health Research Partnership as a Foundation for the Sustainable Development Goals Development of a Dual University System Health Research Partnership as a Foundation for the Sustainable Development Goals GD Morse, JC Lombardo, T Forrester, H Fletcher, A McDonald, A Talal, S Sethi, B

More information

Rare Diseases: Challenges and Opportunities NIH Perspective

Rare Diseases: Challenges and Opportunities NIH Perspective Rare Diseases: Challenges and Opportunities NIH Perspective Stephen C. Groft, Pharm.D. Office of Rare Diseases Research (ORDR) National Center for Advancing Translational Science (NCATS) National Institutes

More information

Introducing your Recruitment Innovation Center. December 2016

Introducing your Recruitment Innovation Center. December 2016 Introducing your Recruitment Innovation Center December 2016 Overview 1. About the RIC 2. CTSA recruitment survey highlights 3. Ways to get involved 4. Questions Vision To become a successful, evidence

More information

NIH GRANTEE SUPPORT FOR MANAGEMENT OF HUMAN SUBJECTS AND CLINICAL TRIALS STUDY INFORMATION

NIH GRANTEE SUPPORT FOR MANAGEMENT OF HUMAN SUBJECTS AND CLINICAL TRIALS STUDY INFORMATION NIH GRANTEE SUPPORT FOR MANAGEMENT OF HUMAN SUBJECTS AND CLINICAL TRIALS STUDY INFORMATION DAWN CORBETT, MPH NIH INCLUSION POLICY OFFICER OFFICE OF EXTRAMURAL PROGRAMS OFFICE OF EXTRAMURAL RESEARCH INCLUSION@MAIL.NIH.GOV

More information

Enabling faster insights to improve clinical trial efficiency and quality

Enabling faster insights to improve clinical trial efficiency and quality Enabling faster insights to improve clinical trial efficiency and quality Clarity, understanding and confidence Every clinical trial has moments when decisive action is needed to set the course for a

More information

NIH Policy Priorities for Clinical Research

NIH Policy Priorities for Clinical Research NIH Policy Priorities for Clinical Research Kathy Hudson, Ph.D. Deputy Director for Science, Outreach, and Policy, NIH Federal Demonstration Partnership January 12, 2015 Topics Clinical Trial Results Reporting

More information

Improve Trial Efficiency & Quality with CTMS

Improve Trial Efficiency & Quality with CTMS Improve Trial Efficiency & Quality with CTMS Rachel Yang, M.D. Ph.D Director, Product Strategy Oracle Health Sciences Global Business Unit Agenda General trends, and challenges of clinical trial industry

More information

McGill ITS Strategic Plan

McGill ITS Strategic Plan McGill Strategic Plan Context: Our 5 Year Roadmap Approved in April 205 Focuses on improvements to the following areas Teaching and Learning Research Student systems Campus Administration Must be cyclically

More information

Department At-A-Glance

Department At-A-Glance Integrated Site Services Functional Role Integrated Site Services (ISS) includes global and country Start-Up and Regulatory units (RSU) and Integrated Patients & Site Services (IPSS). Our department s

More information

Clinical Research at MSU

Clinical Research at MSU Financial Administration Development Program: Clinical Research at MSU Kristen Burt, Office of Regulatory Affairs (ORA) Sharon Schooley, Clinical & Translational Sciences Institute (CTSI) February 24,

More information

Chairman Cole, Ranking Member DeLauro and distinguished members of the

Chairman Cole, Ranking Member DeLauro and distinguished members of the Fiscal Year 2019 House Appropriations Committee Subcommittee on Labor, Health and Human Services, Education and Related Agencies Appropriations Testimony Cynthia A. Bens, Senior Vice President, Public

More information

SOLVING THE PATIENT RECRUITMENT DILEMMA

SOLVING THE PATIENT RECRUITMENT DILEMMA SOLVING THE PATIENT RECRUITMENT DILEMMA Katheryn Shea is Global Biobanking Lead at Brooks Life Sciences. She is an accomplished biobanking expert with 20+ years of industry experience, author of peer-reviewed

More information

Goal 1: Prepare Students for Leading Roles in an Innovation-driven Economy and Global Society

Goal 1: Prepare Students for Leading Roles in an Innovation-driven Economy and Global Society Goal 1: Prepare Students for Leading Roles in an Innovation-driven Economy and Global Society Objective 1.1 Enroll more high-ability students from all societal segments. Strategy 1.1.1 Enhance marketing

More information

Trial Innovation Network Hub Liaison Team Meeting. August 1, 2017

Trial Innovation Network Hub Liaison Team Meeting. August 1, 2017 Trial Innovation Network Hub Liaison Team Meeting August 1, 2017 Network Facts Michelle Culp (Director, NCATS) A Few Trial Innovation Network Facts: (What have we seen in the past year?) Number of proposals

More information

Yale University. Open Data Access Project

Yale University. Open Data Access Project Open Data Access Project A Model for Dissemination and Independent Analysis of Clinical Trial Program Data Funded by a contract with Medtronic, Inc. Rationale A substantial number of clinical trials are

More information

What is the Future of NIH funded Clinical Research in IBD?

What is the Future of NIH funded Clinical Research in IBD? IBD Clinical Trials Workshop What is the Future of NIH funded Clinical Research in IBD? Stephen P. James, M.D. January 13-14, 2017 Future? FY 2015 NIH Awards for IBD related research 338 Awards $128 Million

More information

Clinical Trials Series Part II

Clinical Trials Series Part II Clinical Trials Series Part II Agenda Recap December Presentation J. Schmelz Example: New CT from HSC Investigator Non Cancer Clinical Trial J. Bates, P. Miranda Example: New CT from External Entity Non

More information

Facilitating Antibacterial Drug Development Outlining the Path Forward

Facilitating Antibacterial Drug Development Outlining the Path Forward Facilitating Antibacterial Drug Development Outlining the Path Forward Helen Boucher, MD FIDSA FACP Division of Infectious Diseases and Geographic Medicine Tufts Medical Center Tufts University School

More information

Clinical Messaging in Mendocino and Lake County

Clinical Messaging in Mendocino and Lake County Clinical Messaging in Mendocino and Lake County Carl Henning, M.D. Will Ross Ukiah, California November 2004 v.8f Henning & Ross, November 2004 [ 1 ] Improving Patient Care A new generation of Health Information

More information

Rethinking the Role of IT

Rethinking the Role of IT White Paper Title Rethinking the Role of IT The Second Curve of Health IT Value Authors: Shawna Schueller, Carol Chouinard and Bob Schwyn Fueled by the Meaningful Use (MU) program, healthcare organizations

More information

Nov 14, Jennifer Lewis Commercial IT Millennium Pharmaceuticals. From Vision to Reality and then some Nov 14,

Nov 14, Jennifer Lewis Commercial IT Millennium Pharmaceuticals. From Vision to Reality and then some Nov 14, From Vision to Reality and then some Nov 14, 2007 Jennifer Lewis Commercial IT Millennium Pharmaceuticals From Vision to Reality and then some Nov 14, 2007 1 About Jennifer Lewis Jennifer Lewis Associate

More information

Integrating Trial Data Processes Across Functional Areas using Electronic Data Capture (EDC) Technology

Integrating Trial Data Processes Across Functional Areas using Electronic Data Capture (EDC) Technology Integrating Trial Data Processes Across Functional Areas using Electronic Data Capture (EDC) Technology Authors: Bill Gluck, PhD DATATRAK, VP of Clinical and Consulting Services Lorraine D. Ellis, MS,

More information

An Integrated Approach to Patient Experience Analytics

An Integrated Approach to Patient Experience Analytics An Integrated Approach to Patient Experience Analytics Director of Value Analytics Johns Hopkins Medicine Email: KLee31@jhmi.edu Vision, Mission, and Values Vision Enhance the value of health care services

More information

Guidance on Request for Information on Rapid Response Platform Technologies for Epidemic Preparedness

Guidance on Request for Information on Rapid Response Platform Technologies for Epidemic Preparedness Guidance on Request for Information on Rapid Response Platform Technologies for Epidemic Preparedness Purpose of this request for information The Bill & Melinda Gates Foundation (BMGF; also referred to

More information

CPhA Strategic Plan

CPhA Strategic Plan CPhA Strategic Plan 2017-2020 Mission Advancing the health and well-being of Canadians through excellence in pharmacist care. Vision Pharmacists providing world-class pharmacy leadership. We will achieve

More information

Early Feasibility Studies (EFS) in the U.S. with a Focus on Valvular Heart Disease: Updates, Impact and Future Directions. Chip Hance June 16 th 2017

Early Feasibility Studies (EFS) in the U.S. with a Focus on Valvular Heart Disease: Updates, Impact and Future Directions. Chip Hance June 16 th 2017 Early Feasibility Studies (EFS) in the U.S. with a Focus on Valvular Heart Disease: Updates, Impact and Future Directions Chip Hance June 16 th 2017 Disclosure Statement of Financial Interest I, Robert

More information

All of Us Research Program

All of Us Research Program All of Us Research Program National Minority Quality Forum Stephanie Devaney, PhD Deputy Director, All of Us Research Program June 21, 2018 #joinallofus All of Us Mission and Objectives Nurture relationships

More information

medicines, improving the health of people around the world.

medicines, improving the health of people around the world. TransCelerate BioPharma Inc. is a non-profit organization with a mission to collaborate across the biopharmaceutical research and development community to identify, design and facilitate the implementation

More information

CDER Keynote Address. Patrizia Cavazzoni M.D. Deputy Center Director for Operations CDER/FDA. AAM GRx+Biosims Conference September 5, 2018

CDER Keynote Address. Patrizia Cavazzoni M.D. Deputy Center Director for Operations CDER/FDA. AAM GRx+Biosims Conference September 5, 2018 CDER Keynote Address Patrizia Cavazzoni M.D. Deputy Center Director for Operations CDER/FDA AAM GRx+Biosims Conference September 5, 2018 1 Outline CDER s modernization roadmap Initiatives to facilitate

More information

ClinicalTrials.gov. Why Does it Affect Me? Should I Be Concerned?

ClinicalTrials.gov. Why Does it Affect Me? Should I Be Concerned? ClinicalTrials.gov Why Does it Affect Me? Should I Be Concerned? Meliha Rahmani & Vanessa Hill OSUWMC ClinicalTrials.gov Administrators College of Medicine Office of Research Be aware that Any PowerPoint

More information

A new Model of Vaccine R&D Global Health Public Private Partnership : The Global Health Vaccine Center of Innovation (GHVCI)

A new Model of Vaccine R&D Global Health Public Private Partnership : The Global Health Vaccine Center of Innovation (GHVCI) A new Model of Vaccine R&D Global Health Public Private Partnership : The Global Health Vaccine Center of Innovation (GHVCI) Jean Lang avp R&D sanofi pasteur 9eme Rencontre Nationale des Directeurs de

More information

2016 San Antonio Claude D. Pepper Older Americans Independence Center Pilot and Exploratory Study Core REQUEST FOR APPLICATIONS PILOT PROJECTS

2016 San Antonio Claude D. Pepper Older Americans Independence Center Pilot and Exploratory Study Core REQUEST FOR APPLICATIONS PILOT PROJECTS 2016 San Antonio Claude D. Pepper Older Americans Independence Center Pilot and Exploratory Study Core REQUEST FOR APPLICATIONS PILOT PROJECTS Mission: The major objective of the San Antonio Claude D.

More information

Chandler. The Innovation and Technology Hub of the Southwest! CHIEF INFORMATION OFFICER (CIO)

Chandler. The Innovation and Technology Hub of the Southwest! CHIEF INFORMATION OFFICER (CIO) CITY OF CHANDLER, ARIZONA career opportunity Chandler. The Innovation and Technology Hub of the Southwest! CHIEF INFORMATION OFFICER (CIO) SALARY: $113,755 $167,418 ANNUALLY DOE/DOQ Well recognized as

More information

Business Process Services. White Paper. Reimagining the Clinical Trials Process through Digital Disruption

Business Process Services. White Paper. Reimagining the Clinical Trials Process through Digital Disruption Business Process Services White Paper Reimagining the Clinical s Process through Digital Disruption About the Author Reema Deb Reema has been working with Tata Consultancy Services (TCS) since 2013 in

More information

Data-Driven Strategies for Improved Site Activation and Patient Enrollment Forecasting

Data-Driven Strategies for Improved Site Activation and Patient Enrollment Forecasting Data-Driven Strategies for Improved Site Activation and Patient Enrollment Forecasting Introduction PRESENTERS Mark Shapiro, MA, MBA Vice President, Clinical Development Clinipace Worldwide Cindy Venendaal,

More information

FINANCE & BUSINESS AT PENN STATE...

FINANCE & BUSINESS AT PENN STATE... Table of Contents FINANCE & BUSINESS AT PENN STATE... 3 Mission & Vision... 3 Organizational Profile... 3 F&B Situational Analysis... 3 F&B Alignment with University Priorities... 4 STRATEGIC PRIORITIES...

More information

Delivering the NIHR Central Commissioning Facility

Delivering the NIHR Central Commissioning Facility Delivering the NIHR Central Commissioning Facility About the NIHR The National Institute for Health Research is funded through the Department of Health to improve the health and wealth of the nation through

More information

Technology to Transform Your Clinical Trials

Technology to Transform Your Clinical Trials Technology to Transform Your Clinical Trials DrugDev Spark is the only unified clinical solutions suite with proven success for hundreds of sponsors and CROs Spark Spark TM DrugDev Spark is the answer

More information

The Argonaut Project. July 31, 2015

The Argonaut Project. July 31, 2015 The Argonaut Project July 31, 2015 Health care information shared only through complex XML documents - 1 - Health care information shared only through complex XML documents Federal EHR certification sanctioning

More information

GLOBAL Trend and opportunities in drug development

GLOBAL Trend and opportunities in drug development GLOBAL Trend and opportunities in drug development พญ อรณ ต งเผ า Oranee T Daniels MD October 2015 Looking back during last 15 years Drug safety became a focus for both regulators and drug developers.

More information

A Streamlined Data Capture and Exchange Partnership that Delivers Faster Decisions

A Streamlined Data Capture and Exchange Partnership that Delivers Faster Decisions A Streamlined Data Capture and Exchange Partnership that Delivers Faster Decisions 2011 SAS Health & Life Sciences Conference Michelle Combs, PhD, VP, Clinical Pharmacology Sciences, Celerion Bernd Doetzkies,

More information

FDA Driving Biomedical Product Innovation

FDA Driving Biomedical Product Innovation FDA Driving Biomedical Product Innovation Vicki Seyfert-Margolis, Ph.D. Senior Advisor, Science Innovation and Policy Office of the Commissioner November 12, 2012 1 FDA Mission FDA is charged with protecting

More information

Yale University. Open Data Access Project

Yale University. Open Data Access Project Open Data Access Project A Model for Dissemination and Independent Analysis of Clinical Trial Program Data Funded by a contract with Medtronic, Inc. Session Objectives Why do we need to promote data sharing?

More information

Why Industry Collaboration Matters

Why Industry Collaboration Matters Why Industry Collaboration Matters Jackie Kent Sr. Director, Clinical Development & Optimization (CDIO) & NGD Trial Execution, Eli Lilly and Company Kelly Kirsch Consultant Shared Investigator Platform,

More information

CTSA Program Common Metrics Initiative

CTSA Program Common Metrics Initiative CTSA Program Common Metrics Initiative PI Overview: Maximizing CTSA Program Impact Philip L. Lee Clear Impact www.clearimpact.com Based on the principles of Results-Based Accountability from Trying Hard

More information

Policy Appendix IV: DRCR.net Industry Collaboration Policies Version 5.0, February 2, 2009

Policy Appendix IV: DRCR.net Industry Collaboration Policies Version 5.0, February 2, 2009 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 DRCR.net is committed to: performing rigorous multi-center clinical

More information

Columbus Water Works. Five Year Strategic Plan FY

Columbus Water Works. Five Year Strategic Plan FY Columbus Water Works Five Year Strategic Plan FY 2013-2017 1 1 Our Values Integrity > Dedicated to a standard of values that promotes honesty and openness > Maintain fair and equitable practices to enhance

More information

Acurian on. The Staggering Costs of Clinical Trial Delays and How to Avoid Them. Trial Delays May Be Costing You More than You Realize

Acurian on. The Staggering Costs of Clinical Trial Delays and How to Avoid Them. Trial Delays May Be Costing You More than You Realize Acurian on The Staggering Costs of Clinical Trial Delays and How to Avoid Them Trial Delays May Be Costing You More than You Realize Clinical trials can bring new innovations to the market only when they

More information

Accelerating Clinical Trials Through Access to Real-World Patient Data

Accelerating Clinical Trials Through Access to Real-World Patient Data Accelerating Clinical Trials Through Access to Real-World Patient Data Accelerating Clinical Trials Through Access to Real-World Patient Data Executive Summary: Leveraging Normalized Real-World Patient

More information

NIH Policy on Dissemination of NIH- Funded Clinical Trial Information

NIH Policy on Dissemination of NIH- Funded Clinical Trial Information NIH Policy on Dissemination of NIH- Funded Clinical Trial Information Valery Gordon, Ph.D., M.P.H. Senior Advisor for Human Subjects Protection Division of Clinical Innovation 2018 Spring CTSA Program

More information

SOCIETY OF RESEARCH ADMINISTRATORS ORLANDO FLORIDA OCTOBER 2018

SOCIETY OF RESEARCH ADMINISTRATORS ORLANDO FLORIDA OCTOBER 2018 SOCIETY OF RESEARCH ADMINISTRATORS ORLANDO FLORIDA OCTOBER 2018 CLINICAL TRIALS FINANCIAL MANAGEMENT ADMINISTRATIVE CHALLENGES & CONSIDERATIONS Agenda 1. Introduction 2. Challenges in Clinical Trial Financial

More information

Policy Appendix IV: DRCR.net Industry Collaboration Policies Version 6.0, August 2, 2017

Policy Appendix IV: DRCR.net Industry Collaboration Policies Version 6.0, August 2, 2017 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 DRCR.net is committed to: performing rigorous multi-center clinical

More information

Recommendations for Strengthening the Investigator Site Community

Recommendations for Strengthening the Investigator Site Community Recommendations for Strengthening the Investigator Site Community October 2017 CTTI MISSION: To develop and drive adoption of practices that will increase the quality and efficiency of clinical trials

More information

Perspectives on Large Simple Trials

Perspectives on Large Simple Trials Perspectives on Large Simple Trials Michael S Lauer, MD, FACC, FAHA Director, Division of Cardiovascular Sciences National Heart, Lung, and Blood Institute Financial disclosures: None Clinical Trials Transformation

More information

Process for Solicitation and Review of Clinical Trials for NETT

Process for Solicitation and Review of Clinical Trials for NETT Process for Solicitation and Review of Clinical Trials for NETT 1. Guideline Development Guidelines describing the characteristics that make trials well suited to be performed in the network will be created

More information

Improving Pa-ent Outcomes with Research: The Appliance of Science NIHR UCL Hospitals Biomedical Research Centre

Improving Pa-ent Outcomes with Research: The Appliance of Science NIHR UCL Hospitals Biomedical Research Centre Improving Pa-ent Outcomes with Research: The Appliance of Science NIHR UCL Hospitals Biomedical Research Centre Bryan Williams MD FRCP FESC FAHA Professor of Medicine and BRC Director 29/08/2013 Creating

More information

How is trial registration affecting gjournals?

How is trial registration affecting gjournals? How is trial registration affecting gjournals? Dr Trish Groves Deputy editor, BMJ & Editor in chief, BMJ Open My competing interests Roles at BMJ contributing to, publicising, and leading implementation

More information

The Critical Path to TB Drug Regimens Initiative

The Critical Path to TB Drug Regimens Initiative The Critical Path to TB Drug Regimens Initiative Jan Gheuens, MD, PhD Global Health, Bill & Melinda Gates Foundation Addis Ababa, August 18th, 2010 The new tools that are needed to fight TB are on their

More information

Welcome. Thank you for joining us. Irina Moissiu, Director Client Relations Laurie Furiness, EVP Operations & Consulting Services

Welcome. Thank you for joining us. Irina Moissiu, Director Client Relations Laurie Furiness, EVP Operations & Consulting Services Welcome Thank you for joining us Irina Moissiu, Director Client Relations Laurie Furiness, EVP Operations & Consulting Services 360 o SERVICE PERFORMANCE MEASUREMENT Sponsor View TM 5 Assessments Available

More information

Generating Real-World Evidence

Generating Real-World Evidence Generating Real-World Evidence The Emergence of Pragmatic Clinical Trials Liz Wing, MA Senior Science Writer/Editor Jonathan McCall, MS Senior Science Writer/Editor www.nihcollaboratory.org The NIH Health

More information

NATIONAL PRIORITIES:

NATIONAL PRIORITIES: NATIONAL PRIORITIES: CONTINUOUS MANUFACTURING OF MEDICAL COUNTERMEASURES R. Thomas Warf, Director Manufacturing, Facilities, and Engineering HHS/ASPR/BARDA June 27, 2016 Resilient People. Healthy Communities.

More information

Strategic Plan. Uniting to care & cure

Strategic Plan. Uniting to care & cure 2017-2020 Strategic Plan Uniting to care & cure Table of Contents Message from the President & CEO Page 2 Overview Page 3 Mission Page 4 Core Values Page 5 2017-2020 Objectives & Strategies Page 6 Mission

More information

THE IMPACT OF ADR REPORTING ON SAFE USE OF MEDICINES IN SINGAPORE THE 10-YR EXPERIENCE

THE IMPACT OF ADR REPORTING ON SAFE USE OF MEDICINES IN SINGAPORE THE 10-YR EXPERIENCE THE IMPACT OF ADR REPORTING ON SAFE USE OF MEDICINES IN SINGAPORE THE 10-YR EXPERIENCE Dr John Lim Dr John Lim Chief Executive Officer Health Sciences Authority Singapore 13 October 2006 Ms Chan Cheng

More information